- Home
- FRD vs BNTC Comparison
FRD vs BNTC Comparison
Compare FRD & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- BNTC
- Stock Information
- Founded
- FRD 1965
- BNTC 1995
- Country
- FRD United States
- BNTC United States
- Employees
- FRD N/A
- BNTC N/A
- Industry
- FRD Steel/Iron Ore
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- BNTC Health Care
- Exchange
- FRD Nasdaq
- BNTC Nasdaq
- Market Cap
- FRD 109.9M
- BNTC 88.1M
- IPO Year
- FRD N/A
- BNTC N/A
- Fundamental
- Price
- FRD $13.95
- BNTC $10.30
- Analyst Decision
- FRD
- BNTC Buy
- Analyst Count
- FRD 0
- BNTC 6
- Target Price
- FRD N/A
- BNTC $23.83
- AVG Volume (30 Days)
- FRD 8.9K
- BNTC 82.8K
- Earning Date
- FRD 02-12-2025
- BNTC 02-11-2025
- Dividend Yield
- FRD 1.15%
- BNTC N/A
- EPS Growth
- FRD N/A
- BNTC N/A
- EPS
- FRD 1.14
- BNTC N/A
- Revenue
- FRD $469,515,000.00
- BNTC N/A
- Revenue This Year
- FRD N/A
- BNTC N/A
- Revenue Next Year
- FRD N/A
- BNTC N/A
- P/E Ratio
- FRD $12.28
- BNTC N/A
- Revenue Growth
- FRD N/A
- BNTC N/A
- 52 Week Low
- FRD $13.40
- BNTC $2.70
- 52 Week High
- FRD $19.52
- BNTC $13.29
- Technical
- Relative Strength Index (RSI)
- FRD 35.63
- BNTC 41.00
- Support Level
- FRD $13.96
- BNTC $10.20
- Resistance Level
- FRD $15.57
- BNTC $11.39
- Average True Range (ATR)
- FRD 0.49
- BNTC 0.87
- MACD
- FRD -0.17
- BNTC -0.19
- Stochastic Oscillator
- FRD 0.00
- BNTC 3.58
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.